New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:10 EDTACTActavis announces final stockholder results in Forest Laboratories acquisition
Actavis announced the final results of the elections made by stockholders of Forest Laboratories as to the form of merger consideration they would receive in connection with Actavis' acquisition of Forest. Holders of approximately 13.81% of the outstanding shares of Forest common stock elected to receive 3306 of an Actavis ordinary share and $26.04 in cash, without interest, with fractions of an Actavis ordinary share being cashed out at $219.00 per Actavis ordinary share. Holders of approximately 0.44% of the outstanding Forest shares elected to receive $86.81 in cash, without interest. Holders of approximately 72.78% of the outstanding shares of Forest common stock elected to receive $25.67 in cash plus 0.3326 of an Actavis ordinary share, with fractions of an Actavis ordinary share being cashed out at $219.00. Holders of approximately 12.97% of the outstanding Forest shares failed to make a valid election or did not deliver a valid election form prior to the deadline and will receive the Standard Election Consideration for each Actavis ordinary share, with fractions of an Actavis ordinary share being cashed out at $219.00 per Actavis ordinary share.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
17:50 EDTACTActavis confirms District Court ruling that Atelvia patents are invalid
Subscribe for More Information
March 2, 2015
08:31 EDTACTActavis receives approval from Europcean Commission for Xydalba
Subscribe for More Information
February 27, 2015
08:04 EDTACTActavis and Medicines360 announce FDA approval of LILETTA
Subscribe for More Information
08:02 EDTACTFDA PDUFA Date for Actavis Nebivolol/Valsartan is February 27, 2015
February 25, 2015
17:26 EDTACTActavis' Avycaz for infections approved by FDA
Actavis' Avycaz has been approved by the FDA for the treatment of adult patients with complicated intra-abdominal infections and complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. AVYCAZ received a priority review based on Phase II data from the company's clinical development program and supporting in vitro data, and as such should be reserved for use in patients who have limited or no alternative treatment options. AVYCAZ will be available in Q2.
08:19 EDTACTActavis price target raised to $350 from $315 at Bernstein
Subscribe for More Information
07:59 EDTACTActavis 13.2M share Secondary priced at $288.00
The deal size was lowered to $3.8B from $4.2B and but the convertible preferred was up-sized to $4.6B from $4.2B. JPMorgan, Mizuho, Wells Fargo and Morgan Stanley acted as joint book running managers for the offering.
February 24, 2015
16:27 EDTACTActavis confirms generic Uceris patent challenge
Actavis (ACT) confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Budesonide Extended-release Tablets, 9 mg. Actavis' ANDA product is a generic version of Salix Pharmaceuticals' (SLXP) Uceris, which is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
February 23, 2015
12:53 EDTACTAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
February 20, 2015
08:46 EDTACTActavis receives final approval for generic version of Subutex
Actavis announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex. Actavis intends to begin shipping its product shortly. Subutex is indicated for the treatment of opioid dependence. For the 12 months ending December 31, 2014, Subutex had total U.S. sales of approximately $108M, according to IMS Health data.
08:07 EDTACTActavis price target raised to $340 from $310 at Argus
Argus increased its price target on Actavis as the firm believes that the company is generating strong growth. Argus is upbeat on the company's acquisition of Allergan and keeps a Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use